LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

AnaptysBio Inc

Fechado

SetorSaúde

23.72 12.63

Visão Geral

Variação de preço das ações

24h

Atual

Mín

20.73

Máximo

23.95

Indicadores-chave

By Trading Economics

Rendimento

-18M

-39M

Vendas

-15M

28M

EPS

-1.28

Margem de lucro

-141.619

Funcionários

136

EBITDA

-24M

-28M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+140.59% upside

Dividendos

By Dow Jones

Próximos Ganhos

1 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

29M

642M

Abertura anterior

11.09

Fecho anterior

23.72

Sentimento de Notícias

By Acuity

63%

37%

338 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

AnaptysBio Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de jun. de 2025, 14:31 UTC

Ganhos

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 20:33 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 19:36 UTC

Conversa de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 de jun. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 de jun. de 2025, 18:46 UTC

Conversa de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 de jun. de 2025, 18:02 UTC

Conversa de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 de jun. de 2025, 16:35 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:34 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:21 UTC

Conversa de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

6 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 de jun. de 2025, 15:53 UTC

Conversa de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 15:33 UTC

Conversa de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 de jun. de 2025, 15:16 UTC

Conversa de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 de jun. de 2025, 15:05 UTC

Conversa de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 de jun. de 2025, 14:35 UTC

Conversa de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 de jun. de 2025, 14:15 UTC

Conversa de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 de jun. de 2025, 14:12 UTC

Ganhos

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 de jun. de 2025, 14:09 UTC

Ganhos

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparação entre Pares

Variação de preço

AnaptysBio Inc Previsão

Preço-alvo

By TipRanks

140.59% parte superior

Previsão para 12 meses

Média 50.86 USD  140.59%

Máximo 90 USD

Mínimo 25 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para AnaptysBio Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

9

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

19.25 / 21.135Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

338 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.